Who
Roderick De Greef
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, BioLife Solutions; Director, Pareteum; Director, Endologix Inc /de/; Chairman of the Board, Cambridge Heart.
In numbers
- Trades disclosed
- 376
- Buys
- 1
- Sells
- 102
- Bought
- $30K
- Sold
- $24.9M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 14 Apr 2006
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 4 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —225,670 | filing |
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —237,460 | filing |
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $14.1M364,872 at $38.61 | filing |
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code D | —826,454 | filing |
| 18 Sep 2026filed 22 Sep 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $102K2,775 at $36.69 | filing |
| 18 Sep 2026filed 22 Sep 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $102K2,775 at $36.69 | filing |
| 18 Jun 2026filed 22 Jun 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $72K2,775 at $26.04 | filing |
| 18 Jun 2026filed 22 Jun 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $72K2,775 at $26.04 | filing |
| 19 Mar 2026filed 23 Mar 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $212K11,101 at $19.12 | filing |
| 19 Mar 2026filed 23 Mar 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $212K11,101 at $19.12 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —118,730 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —170,291 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $1.5M67,010 at $22.65 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —219,024 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $2.0M86,186 at $22.65 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —118,730 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —170,291 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $1.5M67,010 at $22.65 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —219,024 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code F | $2.0M86,186 at $22.65 | filing |
News
No headline names them, or the companies they trade most, lately.